Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance

Alicia H. Augustine; Lisa M. Lowenstein; William S. Harris; Gregory C. Shearer; Robert C. Block

doi:10.1016/j.plefa.2013.12.003

Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance

Alicia H. Augustine, Lisa M. Lowenstein, William S. Harris, Gregory C. Shearer, Robert C. Block

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Introduction: The effects of dietary fatty acid supplementation on lipoprotein fatty acid composition have rarely been described. Patients and methods: Sixty-one overweight and obese adults with dyslipidemia and insulin resistance were randomized to placebo, 2. g/day extended-release nicotinic acid (ERN), 4. g/day prescription omega-3 fatty acid ethyl ester (P-OM3), or combination therapy for 16 weeks. Lipoprotein fatty acid composition was analyzed by gas chromatography pre- and post-treatment. Results: Treatment with P-OM3 or combination, but not ERN, increased proportions of eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid, and reduced those for arachidonic acid in all lipoprotein fractions, with greatest impact in the high-density lipoprotein fraction. P-OM3-induced changes in eicosapentaenoic acid within low-density lipoproteins and very low-density lipoproteins were associated with beneficial effects on mean arterial pressure and pulse pressure. Conclusions: P-OM3 supplementation, with or without ERN, was associated with differentially altered lipoprotein fatty acid composition and improved blood pressure parameters.

Original language	English (US)
Pages (from-to)	69-75
Number of pages	7
Journal	Prostaglandins Leukotrienes and Essential Fatty Acids
Volume	90
Issue number	2-3
DOIs	https://doi.org/10.1016/j.plefa.2013.12.003
State	Published - 2014
Externally published	Yes

Keywords

AA
DHA
EPA
Fish oil
HDL
LA
LDL
Nicotinic acid
VLDL

ASJC Scopus subject areas

Clinical Biochemistry
Cell Biology

Access to Document

10.1016/j.plefa.2013.12.003

Cite this

Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance. / Augustine, Alicia H.; Lowenstein, Lisa M.; Harris, William S. et al.
In: Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 90, No. 2-3, 2014, p. 69-75.

Research output: Contribution to journal › Article › peer-review

@article{b1b9b411e45b43f4b381fc541e235790,

title = "Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance",

abstract = "Introduction: The effects of dietary fatty acid supplementation on lipoprotein fatty acid composition have rarely been described. Patients and methods: Sixty-one overweight and obese adults with dyslipidemia and insulin resistance were randomized to placebo, 2. g/day extended-release nicotinic acid (ERN), 4. g/day prescription omega-3 fatty acid ethyl ester (P-OM3), or combination therapy for 16 weeks. Lipoprotein fatty acid composition was analyzed by gas chromatography pre- and post-treatment. Results: Treatment with P-OM3 or combination, but not ERN, increased proportions of eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid, and reduced those for arachidonic acid in all lipoprotein fractions, with greatest impact in the high-density lipoprotein fraction. P-OM3-induced changes in eicosapentaenoic acid within low-density lipoproteins and very low-density lipoproteins were associated with beneficial effects on mean arterial pressure and pulse pressure. Conclusions: P-OM3 supplementation, with or without ERN, was associated with differentially altered lipoprotein fatty acid composition and improved blood pressure parameters.",

keywords = "AA, DHA, EPA, Fish oil, HDL, LA, LDL, Nicotinic acid, VLDL",

author = "Augustine, {Alicia H.} and Lowenstein, {Lisa M.} and Harris, {William S.} and Shearer, {Gregory C.} and Block, {Robert C.}",

note = "Funding Information: AA and LL were supported by the National Heart Lung and Blood Institute Preventive Cardiology T32 granted to Thomas A. Pearson of the University of Rochester ( 5 T32 HL007937 ). Measurements of lipoprotein fatty acids were supported by a grant from GlaxoSmithKline ( LVZ 122790 ). The original trial was supported by the National Institute of Health ( 5 R01 DK061486 ). Abbott (Niaspan {\textregistered} ) and GlaxoSmithKline (Lovaza {\textregistered} ) provided the drugs used in this study.",

year = "2014",

doi = "10.1016/j.plefa.2013.12.003",

language = "English (US)",

volume = "90",

pages = "69--75",

journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",

issn = "0952-3278",

publisher = "Churchill Livingstone",

number = "2-3",

}

TY - JOUR

T1 - Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance

AU - Augustine, Alicia H.

AU - Lowenstein, Lisa M.

AU - Harris, William S.

AU - Shearer, Gregory C.

AU - Block, Robert C.

N1 - Funding Information: AA and LL were supported by the National Heart Lung and Blood Institute Preventive Cardiology T32 granted to Thomas A. Pearson of the University of Rochester ( 5 T32 HL007937 ). Measurements of lipoprotein fatty acids were supported by a grant from GlaxoSmithKline ( LVZ 122790 ). The original trial was supported by the National Institute of Health ( 5 R01 DK061486 ). Abbott (Niaspan ® ) and GlaxoSmithKline (Lovaza ® ) provided the drugs used in this study.

PY - 2014

Y1 - 2014

N2 - Introduction: The effects of dietary fatty acid supplementation on lipoprotein fatty acid composition have rarely been described. Patients and methods: Sixty-one overweight and obese adults with dyslipidemia and insulin resistance were randomized to placebo, 2. g/day extended-release nicotinic acid (ERN), 4. g/day prescription omega-3 fatty acid ethyl ester (P-OM3), or combination therapy for 16 weeks. Lipoprotein fatty acid composition was analyzed by gas chromatography pre- and post-treatment. Results: Treatment with P-OM3 or combination, but not ERN, increased proportions of eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid, and reduced those for arachidonic acid in all lipoprotein fractions, with greatest impact in the high-density lipoprotein fraction. P-OM3-induced changes in eicosapentaenoic acid within low-density lipoproteins and very low-density lipoproteins were associated with beneficial effects on mean arterial pressure and pulse pressure. Conclusions: P-OM3 supplementation, with or without ERN, was associated with differentially altered lipoprotein fatty acid composition and improved blood pressure parameters.

AB - Introduction: The effects of dietary fatty acid supplementation on lipoprotein fatty acid composition have rarely been described. Patients and methods: Sixty-one overweight and obese adults with dyslipidemia and insulin resistance were randomized to placebo, 2. g/day extended-release nicotinic acid (ERN), 4. g/day prescription omega-3 fatty acid ethyl ester (P-OM3), or combination therapy for 16 weeks. Lipoprotein fatty acid composition was analyzed by gas chromatography pre- and post-treatment. Results: Treatment with P-OM3 or combination, but not ERN, increased proportions of eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid, and reduced those for arachidonic acid in all lipoprotein fractions, with greatest impact in the high-density lipoprotein fraction. P-OM3-induced changes in eicosapentaenoic acid within low-density lipoproteins and very low-density lipoproteins were associated with beneficial effects on mean arterial pressure and pulse pressure. Conclusions: P-OM3 supplementation, with or without ERN, was associated with differentially altered lipoprotein fatty acid composition and improved blood pressure parameters.

KW - AA

KW - DHA

KW - EPA

KW - Fish oil

KW - HDL

KW - LA

KW - LDL

KW - Nicotinic acid

KW - VLDL

UR - http://www.scopus.com/inward/record.url?scp=84895906372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895906372&partnerID=8YFLogxK

U2 - 10.1016/j.plefa.2013.12.003

DO - 10.1016/j.plefa.2013.12.003

M3 - Article

C2 - 24378016

AN - SCOPUS:84895906372

SN - 0952-3278

VL - 90

SP - 69

EP - 75

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

IS - 2-3

ER -

Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this